Ablative Solutions gets $77M via Series D; completes fourth tranche bringing proceeds to $91.4M
Executive Summary
Cardiovascular device maker Ablative Solutions Inc. raised $77mm in its Series D financing led by first-time backer Gilde Healthcare, returning investor BioStar Ventures, and an undisclosed new strategic corporate investor. Other existing shareholders Michigan Accelerator Fund, Novus Biotechnology, and individuals also participated. The company will use the funding to finish clinical trials in preparation of US and European regulatory submissions for its minimally invasive Peregrine System, a renal denervation technology to help reduce blood pressure for people with uncontrolled hypertension who are taking antihypertensive medication.
Update 06/13/2022
Ablative Solutions completed the fourth tranche of its Series D financing round, resulting in $91.4mm in aggregate proceeds from the Series D financing round. Gilde Healthcare, BioStar Capital, Invus Opportunities and an undisclosed strategic corporate investor led the multi-tranched Series D round of financing.
Deal Industry
- Medical Devices
-
Medical Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Surgical Equipment & Devices
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice